National Center for Cancer Immune Therapy,
Department of Oncology,
National Center for Cancer Immune Therapy, Department of Oncology
Inge Marie Svane has not added Biography.
If you are Inge Marie Svane and would like to personalize this page please email our Author Liaison for assistance.
Studies on mRNA electroporation of immature and mature dendritic cells: effects on their immunogenic potential.
Molecular biotechnology Oct, 2008 | Pubmed ID: 18543130
CD8 T-cell responses against cyclin B1 in breast cancer patients with tumors overexpressing p53.
Clinical cancer research : an official journal of the American Association for Cancer Research Mar, 2009 | Pubmed ID: 19223507
High immunogenic potential of p53 mRNA-transfected dendritic cells in patients with primary breast cancer.
Breast cancer research and treatment Jan, 2011 | Pubmed ID: 20336365
Identification of a cyclin B1-derived CTL epitope eliciting spontaneous responses in both cancer patients and healthy donors.
Cancer immunology, immunotherapy : CII Feb, 2011 | Pubmed ID: 20981424
Characterization of ex vivo expanded tumor infiltrating lymphocytes from patients with malignant melanoma for clinical application.
Journal of skin cancer , 2011 | Pubmed ID: 21773037
Immunotherapy for metastatic colorectal cancer: present status and new options.
Scandinavian journal of gastroenterology Mar, 2012 | Pubmed ID: 22214467
Tumor associated antigen specific T-cell populations identified in ex vivo expanded TIL cultures.
Cellular immunology , 2012 | Pubmed ID: 22230732
Generation of autologous tumor-specific T cells for adoptive transfer based on vaccination, in vitro restimulation and CD3/CD28 dynabead-induced T cell expansion.
Cancer immunology, immunotherapy : CII Aug, 2012 | Pubmed ID: 22237888
Dissection of T-cell antigen specificity in human melanoma.
Cancer research Apr, 2012 | Pubmed ID: 22311675
FDG PET scans as evaluation of clinical response to dendritic cell vaccination in patients with malignant melanoma.
Cancer immunology, immunotherapy : CII Jan, 2013 | Pubmed ID: 22722450
Characterization of T-cell responses against IκBα in cancer patients.
Oncoimmunology Nov, 2012 | Pubmed ID: 23243592
Analysis of survivin-specific T cells in breast cancer patients using human DCs engineered with survivin mRNA.
Methods in molecular biology (Clifton, N.J.) , 2013 | Pubmed ID: 23296940
Silencing of the glucocorticoid-induced leucine zipper improves the immunogenicity of clinical-grade dendritic cells.
Cytotherapy Jun, 2013 | Pubmed ID: 23643305
The immune checkpoint regulator PD-L1 is a specific target for naturally occurring CD4 T cells.
Oncoimmunology Apr, 2013 | Pubmed ID: 23734334
Broadening the repertoire of melanoma-associated T-cell epitopes.
Cancer immunology, immunotherapy : CII May, 2015 | Pubmed ID: 25854582
Tryptophan 2,3-dioxygenase (TDO)-reactive T cells differ in their functional characteristics in health and cancer.
Oncoimmunology Jan, 2015 | Pubmed ID: 25949861
Indoleamine 2,3-dioxygenase vaccination.
Oncoimmunology Jan, 2015 | Pubmed ID: 25949864
Spontaneous presence of FOXO3-specific T cells in cancer patients.
Oncoimmunology , 2014 | Pubmed ID: 25960934
Reorienting the immune system in the treatment of cancer by using anti-PD-1 and anti-PD-L1 antibodies.
Drug discovery today Sep, 2015 | Pubmed ID: 26189934
Tumor-infiltrating lymphocytes for the treatment of metastatic cancer.
Molecular oncology Dec, 2015 | Pubmed ID: 26578452
Long-Lasting Complete Responses in Patients with Metastatic Melanoma after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes and an Attenuated IL2 Regimen.
Clinical cancer research : an official journal of the American Association for Cancer Research 08, 2016 | Pubmed ID: 27006492
Immune Monitoring Using mRNA-Transfected Dendritic Cells.
Methods in molecular biology (Clifton, N.J.) , 2016 | Pubmed ID: 27236804
Transfection of Tumor-Infiltrating T Cells with mRNA Encoding CXCR2.
Methods in molecular biology (Clifton, N.J.) , 2016 | Pubmed ID: 27236805
Safety, immune and clinical responses in metastatic melanoma patients vaccinated with a long peptide derived from indoleamine 2,3-dioxygenase in combination with ipilimumab.
Cytotherapy 08, 2016 | Pubmed ID: 27378345
Dendritic cell vaccination in combination with docetaxel for patients with metastatic castration-resistant prostate cancer: A randomized phase II study.
Cytotherapy 04, 2017 | Pubmed ID: 28215654
Acquired Immune Resistance Follows Complete Tumor Regression without Loss of Target Antigens or IFNγ Signaling.
Cancer research 09, 2017 | Pubmed ID: 28655789
PD-1 Polyfunctional T Cells Dominate the Periphery after Tumor-Infiltrating Lymphocyte Therapy for Cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research Oct, 2017 | Pubmed ID: 28679768
Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma.
Nature communications 11, 2017 | Pubmed ID: 29170503
Checkpoint inhibitors in breast cancer - Current status.
Cancer treatment reviews Feb, 2018 | Pubmed ID: 29287242
T-cell Responses in the Microenvironment of Primary Renal Cell Carcinoma-Implications for Adoptive Cell Therapy.
Cancer immunology research 02, 2018 | Pubmed ID: 29301752
The inhibitory checkpoint, PD-L2, is a target for effector T cells: Novel possibilities for immune therapy.
Oncoimmunology , 2018 | Pubmed ID: 29308318
Frequent adaptive immune responses against arginase-1.
Oncoimmunology , 2018 | Pubmed ID: 29399404
Cancer immunotherapy in patients with brain metastases.
Cancer immunology, immunotherapy : CII May, 2018 | Pubmed ID: 29520474
[Cancer immunotherapy].
Ugeskrift for laeger May, 2018 | Pubmed ID: 29804567
Spontaneous T-cell responses against the immune check point programmed-death-ligand 1 (PD-L1) in patients with chronic myeloproliferative neoplasms correlate with disease stage and clinical response.
Oncoimmunology , 2018 | Pubmed ID: 29872567
The real-world impact of modern treatments on the survival of patients with metastatic melanoma.
European journal of cancer (Oxford, England : 1990) 02, 2019 | Pubmed ID: 30605822
Tumour-reactive T cell subsets in the microenvironment of ovarian cancer.
British journal of cancer 02, 2019 | Pubmed ID: 30718808
Collagen density regulates the activity of tumor-infiltrating T cells.
Journal for immunotherapy of cancer 03, 2019 | Pubmed ID: 30867051
Correction: Tumour-reactive T cell subsets in the microenvironment of ovarian cancer.
British journal of cancer Apr, 2019 | Pubmed ID: 30890776
MERTK Acts as a Costimulatory Receptor on Human CD8 T Cells.
Cancer immunology research Sep, 2019 | Pubmed ID: 31266785
Real-World Impact of Immune Checkpoint Inhibitors in Metastatic Uveal Melanoma.
Cancers Oct, 2019 | Pubmed ID: 31623302
Arginase-1-based vaccination against the tumor microenvironment: the identification of an optimal T-cell epitope.
Cancer immunology, immunotherapy : CII Nov, 2019 | Pubmed ID: 31690955
Long-Term Exposure to Inflammation Induces Differential Cytokine Patterns and Apoptosis in Dendritic Cells.
Frontiers in immunology , 2019 | Pubmed ID: 31824496
CTLA-4 blockade boosts the expansion of tumor-reactive CD8 tumor-infiltrating lymphocytes in ovarian cancer.
Scientific reports 03, 2020 | Pubmed ID: 32127601
Author Correction: Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma.
Nature communications Apr, 2020 | Pubmed ID: 32238805
In vitro 4-1BB stimulation promotes expansion of CD8 tumor-infiltrating lymphocytes from various sarcoma subtypes.
Cancer immunology, immunotherapy : CII Nov, 2020 | Pubmed ID: 32472369
T-Cell Gene Therapy in Cancer Immunotherapy: Why It Is No Longer Just CARs on The Road.
Cells 06, 2020 | Pubmed ID: 32630096
Escape from nonsense-mediated decay associates with anti-tumor immunogenicity.
Nature communications 07, 2020 | Pubmed ID: 32733040
Future role for adoptive T-cell therapy in checkpoint inhibitor-resistant metastatic melanoma.
Journal for immunotherapy of cancer 07, 2020 | Pubmed ID: 32747469
The metabolic enzyme arginase-2 is a potential target for novel immune modulatory vaccines.
Oncoimmunology 06, 2020 | Pubmed ID: 32923127
The risk of cardiac events in patients receiving immune checkpoint inhibitors: a nationwide Danish study.
European heart journal 04, 2021 | Pubmed ID: 33291147
The capacity of CD4 Vγ9Vδ2 T cells to kill cancer cells correlates with co-expression of CD56.
Cytotherapy 07, 2021 | Pubmed ID: 33785258
Immune Cell Profiling of Peripheral Blood as Signature for Response During Checkpoint Inhibition Across Cancer Types.
Frontiers in oncology , 2021 | Pubmed ID: 33842304
Bone marrow toxicity and immune reconstitution in melanoma and non-melanoma solid cancer patients after non-myeloablative conditioning with chemotherapy and checkpoint inhibition.
Cytotherapy 08, 2021 | Pubmed ID: 33933372
Clinical efficacy of T-cell therapy after short-term BRAF-inhibitor priming in patients with checkpoint inhibitor-resistant metastatic melanoma.
Journal for immunotherapy of cancer 07, 2021 | Pubmed ID: 34210820
Lynch syndrome-associated epithelial ovarian cancer and its immunological profile.
Gynecologic oncology Sep, 2021 | Pubmed ID: 34275654
Adoptive cell therapy with tumor-infiltrating lymphocytes supported by checkpoint inhibition across multiple solid cancer types.
Journal for immunotherapy of cancer Oct, 2021 | Pubmed ID: 34607899
SOBRE A JoVE
Copyright © 2024 MyJoVE Corporation. Todos os direitos reservados